| My Odyssey |
|
|
| Written by Dr. Mel | |||||||||||
| Tuesday, 28 February 2006 | |||||||||||
Page 4 of 9 In my case, I had an early 3- month chemo treatment of Melphalan and Prednisone…a small low dose version which seemed to do little for me, but the cancer protein marker was going down from about 3.2 to 2.5. I began taking Aredia, the bisphosphonate, which years later proved to be a big problem for me. I’ll explain later. And I was taking Epogen shots for my low hematocrit numbers. But, I was on the air full time after just a one-month sabbatical, and although the pain continued, I could get around. The disease seemed relatively stable for about a year, but in the middle of 1998, the pain and cancer protein level were on the march. Something aggressive needed to be done. My colleagues at the TV station have always been supportive of me. They have put up with a lot. Yet, that year, I was voted one of the employees of the year and sent off for a cruise to the Caribbean. My doctor waited for me to return before sharing the “bad” news that we were at a crossroads, and the disease has become far more active. For me, it already seemed active enough. I was shrinking by the week. Actually, since the initial diagnosis, I have shrunk more than 7 inches. But I guess that is OK. I am still well above ground. The question at the time was what treatment direction I might take. Cooper is a transplant specialist, and that seemed to be up there as a high priority for me. Yet, the small dose of chemo didn’t show that I had a lot of promise with that type of therapy, and I was looking for an alternative. It was at that time, fall 1998, when a story came out in USA Today, about a bad old drug that might have an application for being a new form of targeted cancer therapy. The drug was called Thalidomide. The Thalidomide story is a remarkable one, and one that shows how a spouse can step in and make a huge difference in not only the life of a love one, but also countless others. Beth Wolmer’s physician husband was in his last stages of the disease while being treated at the University of Arkansas. Beth combed the literature, the country to find something that might help her husband. At the time, Dr. Judah Folkman at Children’s Hospital in Boston was discovering the important of anti-angiogenesis in suppressing tumor growth. Angiogenesis is the process where blood vessels are extended to tumors and allow them to grow and spread through the body. Anti-angiogenesis cuts off the blood supply. Beth called Folkman and asked if he had anything on the shelf with those anti-angeogenic properties that might be tried for myeloma. He wasn’t positive but thought that Thalidomide might help. He talked with Dr. Barlogie at the University of Arkansas, and Barlogie set up a small trial with three of his patients – including Wolmer. Unfortunately, the Thalidomide did not work for Wolmer. He died. But the other two patients had a dramatic reversal in their disease, and a larger experiment was set up for about three dozen end-stage patients. This was in the spring of 1998. For about a third of the patients, the results showed an impressive reduction of myeloma cells, and soon after, the story caught the eye of the press. The drug was banned around the world earlier because it was used as a sedative for pregnant women and was responsible for horrendous birth defects. But it did seem to have this ability to starve a growing cancer cell, and likely other properties that contributed to the shrinking of the tumors. It also was able to work for those with leprosy, and the FDA had approved its use for that disease. So, it was available again in this country, and because it had been approved for one disease, a doctor could write an off-label prescription for another. I could get it, I just had to convince my doctor. |
|||||||||||
| < Prev | Next > |
|---|
Multiple Myeloma News Update
-
DVT risk increased among patients with multiple myeloma precursor
HemOncToday, NJ - 15 minutes ago
Patients with either multiple myeloma or its precursor condition, monoclonal gammopathy of undetermined significance, may have a higher risk for deep venous ... -
Xencor to Present New Data from Pre-Clinical Antibody Programs at ...
MarketWatch - 7 hours ago
... XmAb5485, Exhibits Potent Activity In Vitro and In Vivo Against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma," on Tuesday, ... -
The International Myeloma Foundation Says Patient Experience ...
MarketWatch - 7 hours ago
Multiple myeloma is a cancer of cells in the bone marrow that affects blood cell production. It cannot be cured, however new therapies used in combination ... -
InforSense Partners With the UK's South London and Maudsley NHS ...
MarketWatch - 12 hours ago
... research into diseases such as Alzheimer's, breast cancer and multiple myeloma," said Jonathan Sheldon, Chief Scientific Officer at InforSense. ...
InforSense Partners With the UK's South London and Maudsley NHS ... International Business Times
all 13 news articles -
Astex presents updates on AT7519 and AT9283 at the American ...
PharmaLive.com (press release), PA - 22 hours ago
Together, these data provide the rationale for further clinical evaluation of AT7519 in the treatment of multiple myeloma and CLL and suggests that AT7519 ... -
Dec 6, 2008 Monthly meeting of the NE TN Multiple Myeloma Support ...
Kingsport Times News, TN - Nov 30, 2008
By Ellen Barrett The Northeast Tennessee Multiple Myeloma Support Group will have it’s next monthly meeting at the Health Resources Center Annex at the Mall ... -
Multiple Myeloma Research Foundation’s (MMRF) annual gala raises ...
Norwalk Plus Magazine - Nov 25, 2008
By Press Release The Multiple Myeloma Research Foundation (MMRF) raised over $1.5 million at its 12th annual "Friends for Life" Fall Gala held on November 1 ... -

HemOncTodayLast decade brought progress in treatment of multiple myeloma
HemOncToday, NJ - Nov 25, 2008
Major strides have been made in the treatment of multiple myeloma in the last decade, with the advent of new agents such as thalidomide, lenalidomide and ...












